Oxford vaccine, 'robust data and no impact on timing'

(ANSA) - ROME, NOVEMBER 27 - The data from the anti-CovidOxford-Irbm-AstraZeneca vaccine "are robust" and the supplementary studies started "will not impact on the expected times".

The next week the data will be published in a scientific journal and "soon", the time to complete the dossier, will be presented to the EMA.

Production of the vaccine candidate "continues" and the first doses will be available as soon as the vaccine is approved.

   ANSA learns this from company sources.

(HANDLE).